Novartis AG (NYSE:NVS) Position Lessened by Kathmere Capital Management LLC

Kathmere Capital Management LLC decreased its position in shares of Novartis AG (NYSE:NVS) by 27.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,954 shares of the company’s stock after selling 4,816 shares during the period. Kathmere Capital Management LLC’s holdings in Novartis were worth $1,261,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NVS. Rhumbline Advisers increased its holdings in Novartis by 1.3% in the second quarter. Rhumbline Advisers now owns 37,810 shares of the company’s stock worth $4,025,000 after buying an additional 499 shares during the last quarter. Thoroughbred Financial Services LLC grew its position in Novartis by 76.0% in the second quarter. Thoroughbred Financial Services LLC now owns 4,719 shares of the company’s stock worth $502,000 after acquiring an additional 2,038 shares in the last quarter. Brown Brothers Harriman & Co. grew its position in Novartis by 16.3% in the second quarter. Brown Brothers Harriman & Co. now owns 55,920 shares of the company’s stock worth $5,953,000 after acquiring an additional 7,823 shares in the last quarter. Wulff Hansen & CO. increased its stake in shares of Novartis by 10,528.6% during the 2nd quarter. Wulff Hansen & CO. now owns 324,171 shares of the company’s stock worth $34,511,000 after purchasing an additional 321,121 shares during the last quarter. Finally, Financial & Tax Architects LLC raised its holdings in shares of Novartis by 32.8% during the 2nd quarter. Financial & Tax Architects LLC now owns 4,703 shares of the company’s stock valued at $501,000 after purchasing an additional 1,161 shares in the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Trading Up 0.1 %

Novartis stock opened at $99.34 on Wednesday. The business has a 50 day moving average price of $101.13 and a two-hundred day moving average price of $109.19. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92. The stock has a market cap of $203.05 billion, a price-to-earnings ratio of 11.54, a price-to-earnings-growth ratio of 1.49 and a beta of 0.57.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Novartis had a return on equity of 34.80% and a net margin of 35.96%. The business had revenue of $12.82 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same period in the prior year, the company posted $1.74 earnings per share. As a group, equities analysts forecast that Novartis AG will post 7.65 EPS for the current year.

Wall Street Analysts Forecast Growth

NVS has been the subject of several recent analyst reports. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. HSBC cut Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Finally, BMO Capital Markets lifted their price target on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research report on Wednesday, October 30th. Two research analysts have rated the stock with a sell rating and seven have assigned a hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $121.50.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.